Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.61 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24287260 | 0.78 | ADORA2A (0.73) | ADORA2ANUDT1ALDH1A1CYP1A2HPGD | |
| SCHEMBL3029368 | 0.78 | ADORA2A (0.79) | ADORA2ANUDT1SCN9ADCPS | |
| SCHEMBL421987 | 0.77 | ADORA2A (1.00) | ADORA2ANUDT1ALDH1A1CYP1A2HPGD | |
| SCHEMBL30979893 | 0.76 | ADORA2A (0.77) | ADORA2ANUDT1ALDH1A1CYP1A2HPGD | |
| SCHEMBL23760187 | 0.76 | ADORA2A (0.71) | ADORA2ANUDT1SCN9ADCPS | |
| Hydrochloric Acid SCHEMBL27344186 | 0.76 | ADORA2A (0.96) | ADORA2ANUDT1ALDH1A1CYP1A2HPGD | |
| SCHEMBL28799984 | 0.75 | DHODH (0.42) | CYP1A2 | |
| SCHEMBL12281655 | 0.74 | ADORA2A (0.92) | ADORA2ANUDT1SCN9ADCPS | |
| SCHEMBL14652511 | 0.74 | PIK3CB (0.41) | ADORA2A | |
| SCHEMBL4794633 | 0.73 | ATR (0.53) | ADORA2ANUDT1ALDH1A1HPGDNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | ADORA2A 1325/4885NUDT1 917/4885ALDH1A1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.